A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards and Recognition

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.

Sustainability

Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Leadership
Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

Premier Comments on DEA Telehealth Proposed Rules

Premier submitted comments to the Drug Enforcement Agency (DEA) on the prescribing of controlled substances via telehealth upon the end of the public health emergency. In its letter, Premier expressed concern that the agency’s approach is too restrictive and fails to build upon the lessons learned during the pandemic, the positive results documented on patient access and outcomes, and the work of other agencies in this area such as recent Substance Abuse and Mental Health Services Administration (SAMHSA) proposals to further reduce restrictions on OUD providers. Therefore, Premier recommends the following:

  • The DEA should align additional flexibilities for the prescribing of controlled substances with the Congressional timeframe for telemedicine extension. Therefore, DEA should consider an approach that permits additional waivers and flexibilities through Dec. 31, 2024 with an intent to further revise and refine based upon the availability of additional data at that juncture.
  • The DEA should permit the prescribing of non-opioid Schedule II controlled substances via telemedicine for mental and behavioral health indications considering the national shortage of mental and behavioral health professionals, especially for the pediatric population. Individual prescriptions should be limited to 30-day supplies and require two-way audio-visual telecommunications (e.g. no audio only). The flexibility should continue through Dec. 31, 2024.
  • The DEA should not permit the prescribing of opioid Schedule II controlled substances via telemedicine.
  • The DEA should permit the prescribing of Schedule III-V controlled substances via telemedicine. Individual prescriptions should be limited to 30-day supplies with no refills. The flexibility should continue through December 31, 2024.
  • The DEA should permit the prescribing of buprenorphine for OUD via telemedicine considering the national shortage of mental and behavioral health professionals. Individual prescriptions should be limited to 90-day supplies with no refills. The flexibility should continue through December 31, 2024.
  • The DEA should hold prescribers accountable for fulfilling the obligations of the practice of medicine when prescribing controlled substances via telemedicine.
  • The DEA should continue to gather data on the impact of prescribing flexibilities from controlled substances on patient access and outcomes while also studying the prevalence of diversion and abuse. The DEA should reissue proposed regulations in advance of expiration of these interim flexibilities in December 2024 to develop a permanent policy that is rooted in evidence.
Login Register Change Registration